At its Annual Meeting of Stockholders held on June 12, 2026, Fate Therapeutics, Inc. stockholders approved a third amendment and restatement of the 2022 Stock Option and Incentive Plan, increasing the maximum number of shares available under the plan by 7,000,000. Additionally, shareholders elected three Class I Directors, ratified Ernst & Young LLP as the independent auditor for fiscal year 2026, and approved a non-binding advisory vote on executive compensation. A total of 87,134,422 shares were represented at the meeting. Fate Therapeutics, Inc. is a biotechnology company focused on developing cell therapies.